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Abstract
Drug name recognition (DNR) is an essential
step in the Pharmacovigilance (PV) pipeline.
DNR aims to find drug name mentions in un-
structured biomedical texts and classify them
into predefined categories. State-of-the-art
DNR approaches heavily rely on hand-crafted
features and domain-specific resources which
are difficult to collect and tune. For this rea-
son, this paper investigates the effectiveness of
contemporary recurrent neural architectures -
the Elman and Jordan networks and the bidi-
rectional LSTM with CRF decoding - at per-
forming DNR straight from the text. The
experimental results achieved on the author-
itative SemEval-2013 Task 9.1 benchmarks
show that the bidirectional LSTM-CRF ranks
closely to highly-dedicated, hand-crafted sys-
tems.
1 Introduction
Pharmacovigilance (PV) is defined by the World
Health Organization as the science and activities
concerned with the detection, assessment, under-
standing and prevention of adverse effects of drugs
or any other drug-related problems. Drug name
recognition (DNR) is a fundamental step in the PV
pipeline, similarly to the well-studied Named En-
tity Recognition (NER) task for general natural lan-
guage processing (NLP). DNR aims to find drug
mentions in unstructured biomedical texts and clas-
sify them into predefined categories in order to link
drug names with their effects and explore drug-drug
interactions (DDIs). Conventional approaches to
DNR sub-divide as rule-based, dictionary-based and
machine learning-based. Intrinsically, rule-based
systems are hard to scale, time-consuming to as-
semble and ineffective in the presence of infor-
mal sentences and abbreviated phrases. Dictionary-
based systems identify drug names by matching text
chunks against drug dictionaries. These systems
typically achieve high precision, but suffer from low
recall (i.e., they miss a significant number of men-
tions) due to spelling errors or drug name variants
not present in the dictionaries (Liu et al., 2015a).
Conversely, machine-learning approaches have the
potential to overcome all these limitations since their
foundations are intrinsically robust to variants. The
current state-of-the-art machine learning approaches
follow a two-step process of feature engineer-
ing and classification (Segura-Bedmar et al., 2015;
Abacha et al., 2015; Rockta¨schel et al., 2013). Fea-
ture engineering refers to the task of representing
text by dedicated numeric vectors using domain
knowledge. Similarly to the design of rule-based
systems, this task requires much expert knowledge,
is typically challenging and time-consuming, and
has a major impact on the final accuracy. For this
reason, this paper explores the performance of con-
temporary recurrent neural networks (RNNs) at pro-
viding end-to-end DNR straight from text, without
any manual feature engineering stage. The tested
RNNs include the popular Elman and Jordan net-
works and the bidirectional long short-term memory
(LSTM) with decoding provided by a conditional
random field (CRF) (Elman, 1990; Jordan, 1986;
Lample et al., 2016; Collobert et al., 2011). The ex-
perimental results over the SemEval-2013 Task 9.1
benchmarks show an interesting accuracy from the
LSTM-CRF that exceeds that of various manually-
engineered systems and approximates the best result
in the literature.
2 Related Work
Most of the research on drug name recognition to
date has focussed on domain-dependent aspects and
specialized text features. The benefit of leveraging
such tailored features was made evident by the re-
sults from the SemEval-2013 Task 9.1 (Recognition
and classification of pharmacological substances,
known as DNR task) challenge. The system that
ranked first, WBI-NER (Rockta¨schel et al., 2013),
adopted very specialized features derived
from an improved version of the ChemSpot
tool (Rockta¨schel et al., 2012), a collection of
drug dictionaries and ontologies. Similarly, many
other recent approaches (Abacha et al., 2015;
Liu et al., 2015b; Segura-Bedmar et al., 2015) have
been based on various combinations of general
and domain-specific features. In the broader
field of machine learning, the recent years have
witnessed a rapid proliferation of deep neural
networks, with unprecedented results in tasks as
diverse as visual, speech and named-entity recog-
nition (Hinton et al., 2012; Krizhevsky et al., 2012;
Lample et al., 2016). One of the main advantages
of neural networks is that they can learn the fea-
ture representations automatically from the data,
thus avoiding the laborious feature engineering
stage (Mesnil et al., 2015; Lample et al., 2016).
Given these promising results, the main goal of this
paper is to provide the first performance investiga-
tion of popular RNNs such as the Elman and Jordan
networks and the bidirectional LSTM-CRF over
DNR tasks.
3 The Proposed Approach
DNR can be formulated as a joint segmentation and
classification task over a predefined set of classes.
As an example, consider the input sentence provided
in Table 1. The notation follows the widely adopted
in/out/begin (IOB) entity representation with, in this
instance, Cimetidine as the drug, ALFENTA as the
brand, and words volatile inhalation anesthetics to-
gether as the group. In this paper, we approach
the DNR task by recurrent neural networks and we
therefore provide a brief description hereafter. In
an RNN, each word in the input sentence is first
mapped to a random real-valued vector of arbitrary
dimension, d. Then, a measurement for the word,
noted as x(t), is formed by concatenating the word’s
own vector with a window of preceding and follow-
ing vectors (the ”context”). An example of input
vector with a context window of size s = 3 is:
w3(t) = [Cimetidine, reduces, effect],
‘reduces′ → xreduces ∈ R
d,
‘Cimetidine′ → xCimetidine ∈ R
d,
‘effect′ → xeffect ∈ R
d,
x(t) = [xCimetidine, xreduces, xeffect] ∈ R
3d
(1)
where w3(t) is the context window centered around
the t-th word, ′reduces′, and xword represents the
numerical vector for word.
For the Elman network, both x(t) and the output
from the hidden layer at time t− 1, h(t− 1), are in-
put into the hidden layer for frame t. The recurrent
connection from the past time frame enables a short-
term memory, while hidden-to-hidden neuron con-
nections make the network Turing-complete. This
architecture, common in RNNs, is suitable for pre-
diction of sequences. Formally, the hidden layer is
described as:
h(t) = f(U • x(t) + V • h(t− 1)) (2)
where U and V are randomly-initialized weight ma-
trices between the input and the hidden layer, and
between the past and current hidden layers, respec-
tively. Function f(·) is the sigmoid function:
f(x) =
1
1 + e−x
(3)
that adds non-linearity to the layer. Eventually, h(t)
is input in the output layer:
y(t) = g(W • h(t)), with g(zm) =
ezm
ΣKk=1e
zk
(4)
and convolved with the output weight matrix, W .
The output is normalized by a multi-class logistic
function, g(·), to become a proper probability over
the class set. The output dimensionality is therefore
determined by the number of entity classes (i.e., 4
for the DNR task).The Jordan network is very sim-
ilar to the Elman network, except that the feedback
Sentence Cimetidine reduces clearance of ALFENTA and volatile inhalation anesthetics
Entity class B-drug O O O B-brand O B-group I-group I-group
Table 1: Example sentence in a DNR task with entity classes represented in IOB format.
DDI-DrugBank DDI-MedLine
Training+Test for DDI task Test for DNR Training+Test for DDI task Test for DNR
documents 730 54 175 58
sentences 6577 145 1627 520
drug n 124 6 520 115
group 3832 65 234 90
brand 1770 53 36 6
drug 9715 180 1574 171
Table 2: Statistics of training and test datasets used for SemEval-2013 Task 9.1.
is sourced from the output layer rather than the pre-
vious hidden layer:
h(t) = f(U • x(t) + V • y(t− 1)). (5)
Although the Elman and Jordan networks
can learn long-term dependencies, their ex-
ponential decay biases them toward their
most recent inputs (Bengio et al., 1994). The
LSTM was designed to overcome this limi-
tation by incorporating a gated memory-cell
to capture long-range dependencies within the
data (Hochreiter and Schmidhuber, 1997). In the
bidirectional LSTM, for any given sentence, the
network computes both a left,
−→
h (t), and a right,
←−
h (t), representations of the sentence context at
every input, x(t). The final representation is created
by concatenating them as h(t) = [−→h (t);←−h (t)]. All
these networks utilize the h(t) layer as an implicit
feature for entity class prediction: although this
model has proved effective in many cases, it is not
able to provide joint decoding of the outputs in a
Viterbi-style manner (e.g., an I-group cannot follow
a B-brand; etc). Thus, another modification to the
bidirectional LSTM is the addition of a conditional
random field (CRF) (Lafferty et al., 2001) as the
output layer to provide optimal sequential decoding.
The resulting network is commonly referred to as
the bidirectional LSTM-CRF (Lample et al., 2016).
4 Experiments
4.1 Datasets
The DDIExtraction 2013 shared task
challenge from SemEval-2013 Task
9.1 (Segura-Bedmar et al., 2013) has provided
a benchmark corpus for DNR and DDI extraction.
The corpus contains manually-annotated pharma-
cological substances and drug-drug interactions
(DDIs) for a total of 18, 502 pharmacological
substances and 5, 028 DDIs. It collates two
distinct datasets: DDI-DrugBank and DDI-
MedLine (Herrero-Zazo et al., 2013). Table 2
summarizes the basic statistics of the training
and test datasets used in our experiments. For
proper comparison, we follow the same settings
as (Segura-Bedmar et al., 2015), using the training
data of the DNR task along with the test data for the
DDI task for training and validation of DNR. We
split this joint dataset into a training and validation
sets with approximately 70% of sentences for
training and the remaining for validation.
4.2 Evaluation Methodology
Our models have been blindly evaluated on un-
seen DNR test data using the strict evaluation
metrics. With this evaluation, the predicted en-
tities have to match the ground-truth entities ex-
actly, both in boundary and class. To facili-
tate the replication of our experimental results,
we have used a publicly-available library for the
implementation1 (i.e., the Theano neural network
toolkit (Bergstra et al., 2010)). The experiments
have been run over a range of values for the
hyper-parameters, using the validation set for se-
lection (Bergstra and Bengio, 2012). The hyper-
parameters include the number of hidden-layer
nodes, H ∈ {25, 50, 100}, the context window size,
s ∈ {1, 3, 5}, and the embedding dimension, d ∈
1https://github.com/raghavchalapathy/dnr
Methods
DDI-DrugBank DDI-MedLine
Precision Recall F1 Score Precision Recall F1 Score
WBI-NER (Rockta¨schel et al., 2013) 88.00 87.00 87.80 61.00 56.00 58.10
Hybrid-DDI (Abacha et al., 2015) 93.00 70.00 80.00 74.00 25.00 37.00
Word2Vec+DINTO (Segura-Bedmar et al., 2015) 69.00 82.00 75.00 65.00 51.00 57.00
Elman RNN 79.91 60.91 69.13 43.23 33.56 37.78
Jordan RNN 77.59 60.91 68.25 59.47 30.20 40.06
Bidirectional LSTM-CRF 87.07 83.39 85.19 52.93 52.57 52.75
Table 3: Performance comparison between the recurrent neural networks (bottom three lines) and state-of-the-art systems (top
three lines) over the SemEval-2013 Task 9.1.
Bidirectional LSTM-CRF
Entities DDI-DrugBank DDI-MedLinePrecision Recall F1 Score Precision Recall F1 Score
group 76.92 90.91 83.33 59.52 53.76 56.50
drug 90.59 84.62 87.50 65.22 61.05 63.06
brand 91.30 79.25 84.85 0.0 0.0 0.0
drug n 0.0 0.0 0.0 40.20 45.45 42.67
Table 4: SemEval-2013 Task 9.1 results by entity for the bidirectional LSTM-CRF.
{50, 100, 300, 500, 1000}. Two additional parame-
ters, the learning and drop-out rates, were sampled
from a uniform distribution in the range [0.05, 0.1].
The embedding and initial weight matrices were all
sampled from the uniform distribution within range
[−1, 1]. Early training stopping was set to 100
epochs to mollify over-fitting, and the model that
gave the best performance on the validation set was
retained. The accuracy is reported in terms of micro-
average F1 score computed using the CoNLL score
function (Nadeau and Sekine, 2007).
4.3 Results and Analysis
Table 3 shows the performance comparison between
the explored RNNs and state-of-the-art DNR sys-
tems. As an overall note, the RNNs have not
reached the same accuracy as the top system, WBI-
NER (Rockta¨schel et al., 2013). However, the bidi-
rectional LSTM-CRF has achieved the second-best
score on DDI-DrugBank and the third-best on DDI-
MedLine. These results seem interesting on the
ground that the RNNs provide DNR straight from
text rather than from manually-engineered features.
Given that the RNNs learn entirely from the data, the
better performance over the DDI-DrugBank dataset
is very likely due to its larger size. Accordingly, it
is reasonable to expect higher relative performance
should larger corpora become available in the fu-
ture. Table 4 also breaks down the results by en-
tity class for the bidirectional LSTM-CRF. The low
score on the brand class for DDI-MedLine and on
the drug n class (i.e., active substances not ap-
proved for human use) for DDI-DrugBank are likely
attributable to the very small sample size (Table 2).
This issue is also shared by the state-of-the-art DNR
systems.
5 Conclusion
This paper has investigated the effectiveness of re-
current neural architectures, namely the Elman and
Jordan networks and the bidirectional LSTM-CRF,
for drug name recognition. The most appealing fea-
ture of these architectures is their ability to pro-
vide end-to-end recognition straight from text, spar-
ing effort from laborious feature construction. To
the best of our knowledge, ours is the first pa-
per to explore RNNs for entity recognition from
pharmacological text. The experimental results
over the SemEval-2013 Task 9.1 benchmarks look
promising, with the bidirectional LSTM-CRF rank-
ing closely to the state of the art. A potential way
to further improve its performance would be to ini-
tialize its training with unsupervised word embed-
dings such as Word2Vec (Mikolov et al., 2013) and
GloVe (Pennington et al., 2014). This approach has
proved effective in many other domains and still dis-
penses with expert annotation effort; we plan this
exploration for the near future.
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